Modality
ERT
MOA
KRASG12Ci
Target
CD123
Pathway
Ferroptosis
RCCEndometrial CaSCD
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
~Sep 2018
→ ~Dec 2019
NDA/BLA
Mar 2020
→ Feb 2025
NDA/BLACurrent
NCT03761833
344 pts·RCC
2020-03→TBD·Terminated
NCT04100562
25 pts·SCD
2024-12→2025-02·Recruiting
369 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-121.1y agoPh3 Readout· SCD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
NDA/BLA
Termina…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2025-02-12 · 1.1y ago
SCD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03761833 | NDA/BLA | RCC | Terminated | 344 | SRI-4 |
| NCT04100562 | NDA/BLA | SCD | Recruiting | 25 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 |